Table 1.
Patient characteristics, demographics, kidney biopsy findings, and treatment course (n = 29)
| Baseline Characteristics | Value |
|---|---|
| Age (yrs) | 73 (61–81) |
| Age (yrs) at KB1 | 59 (54–66) |
| Age (yrs) at KB2 | 65 (55.5–72) |
| Gender | |
| Female | 16 (55%) |
| Male | 13 (45%) |
| Race | |
| Caucasian | 24 (83%) |
| African American | 4 (14%) |
| Others | 1 (3%) |
| Clinical diagnosis | |
| GPA | 10 (34%) |
| MPA | 19 (66%) |
| Organ involvement | |
| Kidney | 29 (100%) |
| Lung | 8 (28%) |
| Sinus | 6 (21%) |
| Skin | 5 (17%) |
| Joint | 3 (10%) |
| Ear, nose and throat | 2 (7%) |
| Nerve | 1 (3%) |
| Indications for KB2 | |
| Elevation in serum creatinine | 16 (55%) |
| Proteinuria | 14 (48%) |
| Persistent hematuria | 10 (34%) |
| New hematuria | 10 (34%) |
| Positive ANCA | 1 (3%) |
| Active ANCA glomerulonephritis in KB2 | 11 (38%) |
| ANCA type at KB1 | |
| Proteinase-3-ANCA | 9 (31%) |
| Myeloperoxidase-ANCA | 17 (58%) |
| Negative-ANCA | 3 (10%) |
| ANCA status at KB2 | |
| Newly positive | 9 (31%) |
| Persistently positive | 8 (28%) |
| Unknown | 6 (21%) |
| Negative | 5 (17%) |
| Serum creatinine (mg/dl) at KB1 | 2 (1.6-4.45) |
| Serum creatinine (mg/dl) at KB2 | 1.9 (1.2-3.8) |
| Histopathological class in KB1 (n = 29) | |
| Focal | 8 (28%) |
| Crescentic | 5 (17%) |
| Mixed | 13 (45%) |
| Sclerotic | 3 (10%) |
| Renal Risk Score in KB1 (n=29) | |
| Low | 8 (28%) |
| Medium | 17 (59%) |
| High | 4 (14%) |
| Histopathological class in KB1 in patients with active ANCA-GN in KB2 (n = 11) | |
| Focal | 3 (27%) |
| Crescentic | 1 (9%) |
| Mixed | 7 (64%) |
| Sclerotic | 0 |
| Histopathological class in KB2 in patients with active ANCA-GN in KB2 (n = 11) | |
| Focal | 3 (27%) |
| Crescentic | 0 |
| Mixed | 5 (45%) |
| Sclerotic | 3 (27%) |
| Renal Risk Score in KB1 in patients with active ANCA-GN in KB2 (n = 11) | |
| Low | 5 (45%) |
| Medium | 5 (45%) |
| High | 1 (3%) |
| Renal Risk Score in KB2 in patients with active ANCA-GN in KB2 (n = 11) | |
| Low | 3 (27%) |
| Medium | 5 (45%) |
| High | 3 (27%) |
| Induction treatment after KB1 | |
| Glucocorticoids | 29 (100%) |
| Cyclophosphamide | 18 (62%) |
| Rituximab | 10 (34%) |
| Mycophenolate Mofetil | 1 (3%) |
ANCA-GN, ANCA-glomerulonephritis; GPA, granulomatosis with polyangiitis; KB1, initial kidney biopsy; KB2, repeat for-cause kidney biopsy; MPA, microscopic polyangiitis.
Data are presented as number of patients (%) or median (interquartile range).